Concepedia

Lawrence W. Updyke

LW

Statistics

Publications

15

Citations

2.7K

H-Index

12

Active since

1988

Affiliations

Pfizer (United States)(Current)

Purdue University West Lafayette

Utah State University

Pfizer (United Kingdom)

University of Arizona

Lawrence W. Updyke is an author at Pfizer (United States) specializing in pharmacology, antiviral pharmacology, and antiviral therapeutics.

Publications per year

1988–2025

15

Publications

15

An oral SARS-CoV-2 M <sup>pro</sup> inhibitor clinical candidate for the treatment of COVID-19

Dafydd R. Owen, Charlotte Allerton, Annaliesa S. Anderson et al. · Science · 2021 · 1.9K citations · Full text

, , +13

Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19

Britton Boras, Rhys Jones, Brandon J. Anson et al. · Nature Communications · 2021 · 296 citations · Full text

, , +15

Discovery of a Novel Inhibitor of Coronavirus 3CL Protease for the Potential Treatment of COVID-19

Britton Boras, Rhys Jones, Brandon J. Anson et al. · bioRxiv (Cold Spring Harbor Laboratory) · 2020 · 159 citations · Full text

, , +17

Task force report: Future research needs for the prevention and management of immune-mediated drug hypersensitivity reactions

N. Franklin Adkinson, David M. Essayan, Rebecca S. Gruchalla et al. · Journal of Allergy and Clinical Immunology · 2002 · 87 citations

, , +16

Reproductive and developmental safety of nirmatrelvir (PF-07321332), an oral SARS-CoV-2 Mpro inhibitor in animal models

Natasha R. Catlin, Christopher Bowman, Sarah N. Campion et al. · Reproductive Toxicology · 2022 · 45 citations · Full text

, , +15

1–5 of 15